Il-6 binding molecules
US-2024158492-A1 · May 16, 2024 · US
Method for the treatment of glomerulonephritis by administering an IL-6 antibody
US9321837B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9321837-B2 |
| Application number | US-67629708-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 4, 2008 |
| Priority date | Sep 6, 2007 |
| Publication date | Apr 26, 2016 |
| Grant date | Apr 26, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a method for the treatment and/or prophylaxis of glomerulonephritis associated with one or more disorders selected from the group consisting of Goodpasture's syndrome, a vasculitic disorder, Wegener's disease, IgA nephropathy and an inflammatory disease with basement membrane involvement comprising administering a therapeutically effective amount of agent which interacts with or modulates the expression or activity of a mammalian IL-6 polypeptide.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating Goodpasture's syndrome or Wegener's disease in a human, the method comprising administering to the human a therapeutically effective amount of an antibody or functionally-active fragment thereof which inhibits activity of a human IL-6 polypeptide. 2. The method according to claim 1 , wherein the antibody is monoclonal, polyclonal, chimeric, humanised or bispecific. 3. The method according to claim 1 , wherein the disorder is Goodpasture's syndrome. 4. The method according to claim 1 , wherein the disorder is Wegener's disease. 5. The method according to claim 1 , wherein said antibody or functionally-active fragment has an effector molecule attached thereto, wherein the effector molecule is a synthetic or a naturally occurring polymer, branched or unbranched polysaccharide, hydroxypropylmethacrylamide (HPMA), albumin, albumin binding protein or albumin binding compound. 6. The method according to claim 5 , wherein the naturally occurring polymer is an optionally substituted straight or branched chain polyalkylene, polyalkenylene or polyoxyalkylene polymer or a branched or unbranched polysaccharide. 7. The method according to claim 5 , wherein the naturally occurring polymer, is lactose, amylose, dextran, glycogen or any derivative thereof. 8. The method of claim 5 , wherein the synthetic polymer is optionally substituted straight or branched chain poly(ethyleneglycol), poly(propyleneglycol) poly(vinylalcohol) or any derivative thereof. 9. The method of claim 8 , wherein the optionally substituted straight or branched chain poly(ethyleneglycol) is methoxypoly(ethyleneglycol) or a derivative thereof.
Assignees
Inventors
Classifications
Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title
comprising antibodies · CPC title
of the kidneys · CPC title
Drugs for disorders of the urinary system · CPC title
- C07K16/248Primary
IL-6 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9321837B2 cover?
- The present invention provides a method for the treatment and/or prophylaxis of glomerulonephritis associated with one or more disorders selected from the group consisting of Goodpasture's syndrome, a vasculitic disorder, Wegener's disease, IgA nephropathy and an inflammatory disease with basement membrane involvement comprising administering a therapeutically effective amount of agent which in…
- Who is the assignee on this patent?
- Marshall Diane, Shaw Stevan, Ucb Pharma Sa
- What technology area does this patent fall under?
- Primary CPC classification C07K16/248. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).